EMA Authorised: Increlex (Mecasermin) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

The European Medicines Agency authorised Increlex (mecasermin) for Laron syndrome, with Esteve Pharmaceuticals, S.A. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laron Syndrome

Drugs mentioned

• INCRELEX (Mecasermin)

Snippet

Status: Authorised. Therapeutic area: Laron Syndrome. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 30/03/2026